Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim for the prevention of severe neutropenia, in patients with breast cancer receiving myelosuppressive chemotherapy.

Authors

Andriy Krendyukov

HEXAL AG, Holzkirchen, Germany

Andriy Krendyukov , Nadia Harbeck , Pedro Gascon , Sreekanth Gattu , Yuhan Li , Kimberly L. Blackwell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A randomized, multicenter clinical trial to determine the efficacy and safety of pegfilgrastim (GEMA BIOTECH) compared to pegfilgrastim (Roche) for prevention of chemotherapy induced neutropenia in patients with breast cancer.

First Author: Martin Eduardo Richardet

insert_chart_outlined

Poster

2021 ASCO Quality Care Symposium

bookmark_border

Real-world utilization and costs with biosimilar and reference filgrastim in patients with breast cancer receiving myelosuppressive chemotherapy in a community oncology setting from 2015 to 2017.

First Author: Robert M. Rifkin

insert_chart_outlined

Poster

2023 ASCO Quality Care Symposium

bookmark_border

Patient characteristics associated with myelosuppression among patients with extensive-stage small cell lung cancer treated with chemotherapy in the community oncology setting.

First Author: Jerome H. Goldschmidt

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC).

First Author: Astrid Paulus